This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imoto, I. Articles by Inazawa, J. Search for Related Content PubMed PubMed Citation Articles by Imoto, I. Articles by Inazawa, J.

Frequent Silencing of the Candidate Tumor Suppressor PCDH20 by Epigenetic Mechanism in Non–Small-Cell Lung Cancers

¹ Department of Molecular Cytogenetics, Medical Research Institute and Graduate School of Biomedical Science, ² Thoracic and Cardiovascular Surgery, and ³ Center of Excellence Program for Frontier Research on Molecular Destruction and Reconstitution of Tooth and Bone, Tokyo Medical and Dental University; ⁴ Core Research for Evolutional Science and Technology of Japan Science and Technology Corporation; ⁵ Tokyo Kyosai Hospital; and ⁶ Pathology Division and ⁷ Cancer Genomics Project, National Cancer Center Research Institute, Tokyo, Japan

Requests for reprints: Johji Inazawa, Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. Phone: 81-3-5803-5820; Fax: 81-3-5803-0244; E-mail: johinaz.cgen{at}mri.tmd.ac.jp.

Protocadherins are a major subfamily of the cadherin superfamily, but little is known about their functions and intracellular signal transduction. We identified a homozygous loss of protocadherin 20 (PCDH20, 13q21.2) in the course of a program to screen a panel of non–small-cell lung cancer (NSCLC) cell lines (1 of 20 lines) for genomic copy number aberrations using an in-house array-based comparative genomic hybridization. PCDH20 mRNA was expressed in normal lung tissue but was not expressed in the majority of NSCLC cell lines without a homozygous deletion of this gene (10 of 19 lines, 52.6%). Expression of PCDH20 mRNA was restored in gene-silenced NSCLC cells after treatment with 5-aza 2'-deoxycytidine. The DNA methylation status of the PCDH20 CpG-rich region correlated inversely with the expression of the gene and a putative target region for methylation showed clear promoter activity in vitro. Methylation of this PCDH20 promoter was frequently observed in primary NSCLC tissues (32 of 59 tumors, 54.2%). Among our primary NSCLC cases, the methylated PCDH20 seemed to be associated with a shorter overall survival (P = 0.0140 and 0.0211 in all and stage I tumors, respectively; log-rank test), and a multivariate analysis showed that the PCDH20 methylation status was an independent prognosticator. Moreover, restoration of PCDH20 expression in NSCLC cells reduced cell numbers in colony formation and anchorage-independent assays. These results suggest that epigenetic silencing by hypermethylation of the CpG-rich promoter region of PCDH20 leads to loss of PCDH20 function, which may be a factor in the carcinogenesis of NSCLC. (Cancer Res 2006; 66(9): 4617-26)

This article has been cited by other articles:

				R. Kikuchi, H. Tsuda, K.-i. Kozaki, Y. Kanai, T. Kasamatsu, K. Sengoku, S. Hirohashi, J. Inazawa, and I. Imoto Frequent Inactivation of a Putative Tumor Suppressor, Angiopoietin-Like Protein 2, in Ovarian Cancer Cancer Res., July 1, 2008; 68(13): 5067 - 5075. [Abstract] [Full Text] [PDF]

				R. Kikuchi, H. Tsuda, Y. Kanai, T. Kasamatsu, K. Sengoku, S. Hirohashi, J. Inazawa, and I. Imoto Promoter Hypermethylation Contributes to Frequent Inactivation of a Putative Conditional Tumor Suppressor Gene Connective Tissue Growth Factor in Ovarian Cancer Cancer Res., August 1, 2007; 67(15): 7095 - 7105. [Abstract] [Full Text] [PDF]